《大行報告》富瑞上調名創優品(09896.HK)目標價至44.7元 評級「買入」
富瑞發表報告,相信名創優品(09896.HK)截至去年12月底止2023財年第二季的海外市場強勁增長,將可抵銷內地經營因疫情而表現疲弱。該行預期,集團季度經調整純利將上升47%至3.17億元人民幣,同期銷售則下跌7%至25.7億元人民幣。
該行上調名創優品港股目標價,由25.2元升至44.7元,評級維持「買入」,並調升集團2023至2025財年盈利預測分別14%、22%及22%,最新預期集團2023財年的銷售增長將達30%,其中內地料升27%,海外更升36%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.